A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

The researchers aimed to assess the effects of omega-3 fatty acid supplementation on albuminuria, blood pressure, pulse wave velocity, and inflammatory markers in patients with CKD.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

The study was double blind.

At baseline, 6 weeks, and 12 weeks, fasting blood and morning spot urine samples were obtained.

Blood pressure, carotid intima media thickness, and pulse wave velocity were measured.

What Was Measured

Topics PubMed links to this paper include Albuminuria, Biomarkers, Blood Pressure, Chile, Dietary Supplements, Fatty Acids, Omega-3 and Pulse Wave Analysis.

What This Means in Plain Language

The paper is a randomized and double-blind study of Copper (Supplement).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.